glp-1 alcohol cravings IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target GLP1 receptor agonists are supported
Description
Sustained GLP-1 signaling also possesses additional benefits: appetite and concomitant weight reduction, and cardioprotective benefits
Certain medications mimic its effects to help people manage type 2 diabetes, and in some cases, lose weight
GLP #2 is also FDA-approved for weight loss treatments (Zepbound and Mounjaro are some name brands)
Diabetic kidney disease: a report From an ADA Consensus Conference
